OBSV - ObsEva SA

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

ObsEva SA

Chemin des Aulx, 12
Plan-les-Ouates 1228
41 22 552 38 40

Full Time Employees43

Key Executives

NameTitlePayExercisedYear Born
Dr. Ernest LoumayeCo-Founder, CEO & DirectorN/AN/A1952
Mr. Timothy M. AdamsChief Financial OfficerN/AN/A1960
Dr. Jean-Pierre Gotteland Ph.D.Chief Scientific Officer and Head of R&DN/AN/A1965
Mr. Mario Vincent CorsoSr. Director of Investor RelationsN/AN/AN/A
Ms. Delphine RenaudPersonal Assistant to the CSO and Head of R&DN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age. The company was founded in 2012 and is headquartered in Plan-les-Ouates, Switzerland.

Corporate Governance

ObsEva SA’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.